RedHill Biopharma (RDHL) announced that the China National Intellectual Property Administration has formally allowed a critical use of composition-of-matter patent for RedHill’s proprietary investigational compound RHB-107, a potential oral treatment for COVID-19. Data from RHB-107’s U.S. Phase 2 study showed a 100% reduction in hospitalization due to COVID-19, with zero patients on the RHB-107 arms versus 15% hospitalized for COVID-19 on the placebo-controlled arm. The study also showed an approximately 88% reduction in reported new severe COVID-19 symptoms after treatment initiation, with new severe COVID-19 symptoms reported by only 2.4% of the RHB-107 treated group compared to 20% of patients in the placebo-controlled arm. Further post-hoc analysis showed faster recovery periods from severe COVID-19 symptoms with a median of 3 days to recovery with RHB-107 compared to 8 days with placebo. Additional clinical data is expected from the externally non-dilutive funded PROTECT study, supported by the U.S. Department of Defense.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDHL:
- RedHill Biopharma Reports 2024 Financial Results and Strategic Progress
- RedHill Biopharma Faces Nasdaq Compliance Challenge
- RedHill Biopharma receives non-compliance letter from Nasdaq
- RedHill Biopharma’s Opaganib Shows Promise in Obesity and Diabetes Market Disruption
- RedHill Biopharma announces publication in journal on Opaganib
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue